SomaLogic

SomaLogic is a privately owned American protein biomarker discovery and clinical diagnostics company[1] located in Boulder, Colorado.

SomaLogic
private
IndustryHealth information
Founded2000
FounderLarry Gold
Headquarters
Boulder, Colorado
,
United States
Websitewww.somalogic.com

Company

The company was founded in 2000 by Larry Gold, who served as both Chairman of the Board of Directors and as the company’s first CEO. In 2013, Byron Hewett was appointed as CEO,[2] with Gold continuing to serve as Chairman.[3] Gold previously founded the pharmaceutical company NeXstar Pharmaceuticals, which merged with Gilead in 1999.[4][5] Hewett stepped down in 2017 and board member Alister Reynolds was appointed the new CEO,[6] who was replaced by Roy Smythe in 2018.[7]

Systems

The company monitors health and disease through the analysis of protein concentration changes in biological samples.[8] They developed the SomaScan platform, which allows scientists and researchers to identify protein biomarkers for diseases and conditions, and apply them to drug and diagnostic research and development.[9] The hypothesis behind the analysis is that different diseases and conditions each have novel protein profiles, including in early stages of onset. As of 2013, the commercial version of the SomaScan platform could identify and quantify 1,129 protein analytes simultaneously.[4] As of 2017, the number had increased to about 4,200.[10] The platform is based on modified-aptamer binding technology (“SOMAmers”) that bind to their respective target proteins in order to determine their presence and quantity in a sample.[11][12][13]

Partnerships

In 2013, the company partnered with Agilent Technologies to distribute SomaScan systems to American research and educational institutions. They also signed a development deal with Quest Diagnostics to create a blood test for early-stage, non-small-cell lung cancer.[4][14] They also have partnerships with Otsuka and New England Biolabs.[15] In 2016, a study was published that used the SomaLogic system to identify nine biomarker proteins that could predict the risk of a second heart attack in those who have suffered a previous cardiovascular event.[10][16] A study in Circulation also used the 9-protein cardiovascular risk score for early detection of the harmful effects of Torcetrapib.[17] In 2016 they also developed a test to diagnose latent tuberculosis, and to predict the progression of the disease after onset.[18] In 2019, a study was published that used the SomaScan platform to build protein-based models for 11 different health indications: liver fat, kidney filtration, percentage body fat, visceral fat mass, lean body mass, cardiopulmonary fitness, physical activity, alcohol consumption, cigarette smoking, diabetes risk, and primary cardiovascular event risk.[19]

The company has a long-term partnership with the Novartis Institutes for BioMedical Research, with Novartis taking an ownership stake in SomaLogic in 2014 as a part of the extension of their initial agreement.[9] In 2016, SomaLogic formed a collaborative partnership with Oxford University,[20] and in 2017 joined the iCarbonX Digital Life Alliance (including an investment by iCarbonX in SomaLogic).[21] In 2018 SomaLogic teamed with the Leeds Centre for Personalised Health and Medicine to test the SomaScan platform in clinical studies in the UK.[22] That year SomaLogic also began to package its insights as diagnostic information for sale to other companies, focusing on proteomic data.[23] In 2019, SomaLogic began commercially offering health information tests on the SomaScan Platform to prescribing physicians in Colorado.[24]

gollark: Of course. Well, your name.
gollark: Trademark transferred.
gollark: Blockchain?!?!??!
gollark: .
gollark: Okay, trademark transfer ready

References
  1. "Term Sheet — Tuesday, March 1". Fortune.com. Retrieved 26 November 2017.
  2. "INterview with Bryron Hewett, CEO of SomaLogic". Innovationsews.com. 26 January 2016. Retrieved 26 November 2017.
  3. "SomaLogic Names New CEO; Founder Larry Gold to Stay on as Chairman - Xconomy". Xconomy.com. 3 December 2013. Retrieved 26 November 2017.
  4. "SomaLogic Partners with Agilent to Distribute Proteomic Technology - Xconomy". Xconomy.com. 13 August 2013. Retrieved 26 November 2017.
  5. "Gilead Sciences and NeXstar Pharmaceuticals to Merge - Gilead". Gilead.com. Retrieved 26 November 2017.
  6. "People in the News: Alister Reynolds, Erik Phelps, and James Heath". Retrieved 26 November 2017.
  7. "Slone Partners Finds New CEO for SomaLogic". 3 December 2018.
  8. "PatientsLikeMe Nabs $100M, Works to Advance Personalized Medicine - Xconomy". Xconomy.com. 6 January 2017. Retrieved 26 November 2017.
  9. "Somalogic Lands Funding After Novartis Extends". Bizjournals.com. Retrieved 26 November 2017.
  10. Cyranoski, David (12 January 2017). "Chinese AI company plans to mine health data faster than rivals". Nature. 541 (7636): 141–142. Bibcode:2017Natur.541..141C. doi:10.1038/541141a. PMID 28079091.
  11. Chi, Kelly Rae (March 31, 2014). "High-Density Info". The Scientist Magazine.
  12. Rastogi, S. C.; Rastogi, Parag; Mendiratta, Namita (2008). Bioinformatics Methods And Applications: Genomics Proteomics And Drug Discovery (3rd ed.). PHI Learning Pvt. Ltd. p. 362. ISBN 978-81-203-3595-0.
  13. Keeney, Tracy R.; Bock, Christopher; Gold, Larry; Kraemer, Stephan; Lollo, Bridget; Nikrad, Malti; Stanton, Martin; Stewart, Alex; Vaught, Jonathan D.; Walker, Jeffrey J. (December 2009). "Automation of the SomaLogic Proteomics Assay: A Platform for Biomarker Discovery". Journal of the Association for Laboratory Automation. 14 (6): 360–366. doi:10.1016/j.jala.2009.05.003.
  14. Powell, Kendall (8 October 2014). "New platform for cataloging hundreds of proteins gets test drive". Nature Medicine. 20 (10): 1082–1083. doi:10.1038/nm1014-1082. PMID 25295926.
  15. "People to Watch : Larry Gold". Bizjournals.com. Retrieved 26 November 2017.
  16. Ganz, Peter; Heidecker, Bettina; Hveem, Kristian; Jonasson, Christian; Kato, Shintaro; Segal, Mark R.; Sterling, David G.; Williams, Stephen A. (21 June 2016). "Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease". JAMA. 315 (23): 2532–41. doi:10.1001/jama.2016.5951. PMID 27327800.
  17. Williams, Stephen A.; Murthy, Ashwin C.; DeLisle, Robert K.; Hyde, Craig; Malarstig, Anders; Ostroff, Rachel; Weiss, Sophie J.; Segal, Mark R.; Ganz, Peter (6 March 2018). "Improving Assessment of Drug Safety Through Proteomics". Circulation. 137 (10): 999–1010. doi:10.1161/CIRCULATIONAHA.117.028213. PMC 5839936. PMID 28974520.
  18. "SomaLogic Developing Tests to Diagnose Latent Tuberculosis, Predict Progression". Genomeweb.com. Retrieved 26 November 2017.
  19. Williams, Stephen A.; Kivimaki, Mika; Langenberg, Claudia; Hingorani, Aroon D.; Casas, J. P.; Bouchard, Claude; Jonasson, Christian; Sarzynski, Mark A.; Shipley, Martin J.; Alexander, Leigh; Ash, Jessica; Bauer, Tim; Chadwick, Jessica; Datta, Gargi; DeLisle, Robert Kirk; Hagar, Yolanda; Hinterberg, Michael; Ostroff, Rachel; Weiss, Sophie; Ganz, Peter; Wareham, Nicholas J. (December 2019). "Plasma protein patterns as comprehensive indicators of health". Nature Medicine. 25 (12): 1851–1857. doi:10.1038/s41591-019-0665-2. PMC 6922049. PMID 31792462.
  20. "University and SomaLogic announce agreement for discovery". University of Oxford. 8 February 2016.
  21. "China's iCarbonX Invests in SomaLogic, Grows Medical Data Alliance". Genomeweb.com. Retrieved 26 November 2017.
  22. "Boulder's SomaLogic to partner with UK medical center". Daily Camera Boulder. February 8, 2018.
  23. Adam Bonislawski (January 18, 2018). "Somalogic Exploring New Models for Selling Clinical Products Based on SomaScan System". GenomeWeb.
  24. "SomaLogic launches its firsts SomaSignal tests in Colorado". 5 September 2019.

www.somalogic.com

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.